Treatment of renal-cell carcinoma has progressed over the past decade, in terms of surgical and systemic therapy.
Current treatment guidelines are based on clinical evidence, but do not take into account resource limitations among different countries. These limitations, which include financial and logistical challenges and lack of skilled health-care professionals, have the greatest effect in low-income countries. This consolidated statement gives treatment recommendations for renal-cell carcinoma that are based on clinical evidence and stratified according to extent of resource availability. The statement was formulated by a panel of urologists, medical oncologists, and clinical oncologists from Asian countries, at a consensus session on kidney cancer that was held as part of the 2012 Asian Oncology Summit in Singapore. Resource levels are defined according to a four-tier system (basic, limited, enhanced, and maximum), and treatment recommendations are specified based on availability of financial, skill, and logistical resources.
Written by:
Chiong E, Tay MH, Tan MH, Kumar S, Sim HG, Teh BT, Umbas R, Chau NM. Are you the author?
Department of Urology, National University Health System, Singapore.
Reference: Lancet Oncol. 2012 Nov;13(11):e482-91.
doi: 10.1016/S1470-2045(12)70433-3
PubMed Abstract
PMID: 23117003
UroToday.com Renal Cancer Section
